Overview:
Anemia is associated with major complications for patients with CKD, including impaired cognition, sleep disturbance, increased cardiac risk, lower QoL, increased medical expense, and increased mortality. Conventional treatment of anemia in these patients has focused on the use of exogenously administered erythropoietin, with intravenous (IV) iron as required to support ongoing hematopoiesis. While the benefits of such therapy are well-established, there are several limitations, including increased risks of cardiovascular (CV) and cerebrovascular events.
Recently approved and emerging agents may address some of the shortcomings of the conventional treatments for CKD. This symposium will employ a case-based discussion format, allowing clinicians to review the current management of anemia in patients with CKD and clinical data on emerging data.
Learning Objectives:
Upon completion of this activity, participants will be able to:
Volker H. Haase, MD
The Krick-Brooks Chair in Nephrology
Professor of Medicine, and Molecular Physiology and Biophysics
Program in Cancer Biology
Division of Nephrology & Hypertension
Vanderbilt University Medical Center
Nashville, TN
Disclosures: Consultant: GlaxoSmithKline, Akebia Therapeutics
Mark J. Koury, MD
Vanderbilt University Medical Center
University of North Carolina Hospitals
Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital
University of Virginia School of Medicine
Professor, Medicine, Vanderbilt University School of Medicine
Nashville, TN
Disclosures: Consultant: GlaxoSmithKline, Akebia Therapeutics
Csaba P. Kovesdy, MD FASN
The Fred Hatch Professor of Medicine
Director, Clinical Trials and Clinical Outcomes Program in Nephrology
Medical Director, Clinical Trials Unit
University of Tennessee Health Science Center
Nephrology Section Chief, Memphis VA Medical Center
Memphis, TN
Disclosures: Consultant: Abbott, Akebia, Astra Zeneca, Bayer, Boehringer Ingelheim, Cara Therapeutics, CSL Vifor, GSK, Pharmacosmos, Takeda, ProKidney
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.